Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Down 52.3% in May

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the target of a large drop in short interest in May. As of May 15th, there was short interest totaling 4,060,180 shares, a drop of 52.3% from the April 30th total of 8,509,923 shares. Currently, 12.1% of the company’s stock are sold short. Based on an average daily volume of 3,052,240 shares, the days-to-cover ratio is currently 1.3 days.

Theriva Biologics Stock Performance

TOVX stock traded up $0.00 during mid-day trading on Tuesday, reaching $0.29. 1,061,709 shares of the stock traded hands, compared to its average volume of 1,786,428. The firm has a market capitalization of $9.65 million, a PE ratio of -0.01 and a beta of 1.10. The business has a 50-day moving average of $0.29 and a two-hundred day moving average of $0.24. Theriva Biologics has a 52 week low of $0.16 and a 52 week high of $0.86. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.11.

Theriva Biologics (NYSEAMERICAN:TOVX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.05) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Theriva Biologics

A hedge fund recently raised its stake in Theriva Biologics stock. Geode Capital Management LLC grew its position in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 212,087 shares of the company’s stock after buying an additional 183,878 shares during the quarter. Geode Capital Management LLC owned approximately 0.63% of Theriva Biologics worth $45,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 6.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Maxim Group upgraded shares of Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $1.00.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.